drugset / Trial / NCT00780494
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical controls.
Timeline
- Start
- 2009-02
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 850 mg/m2 | Oral |
| Subject | Carboplatin | Small molecule | — | Intravenous |